Morepen Laboratories Ltd – RECORD Q2 REVENUE AND EBITDA
Financial results for the quarter and half year ended September 30, 2026:
- Q2 FY27 Revenue: INR 755 Cr, up 81% YoY
- Q2 FY27 EBITDA: INR 132 Cr, up 273% YoY
- Q2 FY27 PAT: INR 89 Cr, up 117% YoY
- Q2 CDMO Revenue: INR 253 Cr (52% of API + CDMO revenue)
- Q2 Exports: INR 397 Cr, up 131% YoY
- Q2 Medical Devices: INR 208 Cr, up 65% YoY